Close Menu

NEW YORK – Personalis reported Monday that it anticipates an 11 percent increase in its 2020 fourth quarter revenues compared to the same period of 2019.

For the quarter ended Dec. 31, 2020, the Menlo Park, California-based precision oncology and population genomics company estimated earnings of $20.2 million in the fourth quarter of 2020 compared with $18.2 million in Q4 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.